Marlboro's Metamorphosis: Big Tobacco's Desperate Pivot to 'Wellness'

In 2024, Philip Morris International (PMI) spent over $1 billion marketing something unprecedented for a tobacco giant: a future without cigarettes. The company's flagship smoke-free products—IQOS heated tobacco devices and Zyn nicotine pouches—now account for nearly 40% of its revenue, up from less than 5% a decade ago. CEO Jacek Olczak has publicly declared that cigarettes will one day be 'a relic of the past' and that PMI intends to be the company that makes that happen. It's an audacious pivot from a corporation whose subsidiary, Philip Morris USA, was found by a federal judge in 2006 to have engaged in a decades-long racketeering conspiracy to defraud the American public about the dangers of smoking. The question isn't whether the transformation is real—it's whether it's trustworthy.

The numbers tell a story of genuine, market-driven change. Global cigarette volumes are declining by roughly 3–5% annually in developed markets, and even faster in some regions. PMI's flagship smoke-free product, IQOS—a device that heats tobacco rather than burning it—has attracted over 30 million users worldwide, with particularly strong adoption in Japan, where cigarette sales have plummeted by over 40% since IQOS launched. British American Tobacco (BAT) has followed suit with its 'glo' device and Vuse vaping products, while Altria (PMI's former parent) has diversified into cannabis and oral nicotine. The industry is betting tens of billions that the future of nicotine is not combustible. Whether that bet is driven by altruism or survival instinct is, for the consumer, less relevant than whether the alternative products are actually safer.

But trust is earned, not claimed—and tobacco companies have an extraordinary trust deficit to overcome. The industry's history of deception is not ancient history. As recently as 2019, a Reuters investigation revealed that PMI's own clinical studies showed IQOS emissions contained toxic compounds at levels that raised internal concern, even as the company was publicly promoting the device as a 'reduced risk' product. The FDA ultimately authorized IQOS for sale in the U.S. but explicitly withheld the 'modified risk' designation that would have allowed PMI to market it as safer than cigarettes. The agency's mixed signal captures the core dilemma: the products may well be less harmful, but the company promoting them spent the 20th century perfecting the art of lying about product safety.

The Zyn phenomenon illustrates a newer and arguably more disruptive trend: nicotine products that contain no tobacco at all. Zyn pouches—small sachets of nicotine salt, flavoring, and plant fiber placed between the gum and lip—have exploded in popularity, particularly among young adult males. Unlike vaping, Zyn produces no aerosol, leaves no smell, and can be used anywhere. It's 'tobacco-free nicotine,' a category that occupies an awkward regulatory gap in most countries—not a tobacco product, not a pharmaceutical, not a food. The FDA has yet to establish a comprehensive framework for these products, even as sales have grown by triple-digit percentages year over year. In May 2026, the WHO explicitly warned that nicotine pouch brands are targeting youth through social media marketing—the same playbook that made disposables a schoolyard staple.

The industry's transformation narrative also conveniently sidesteps a stubborn fact: cigarettes remain enormously profitable, especially in developing markets where regulation is weak and smoking rates remain high. PMI, BAT, and Japan Tobacco International continue to aggressively market combustible cigarettes across Africa, Southeast Asia, and Latin America, often employing tactics—like targeting women and youth, opposing tax increases, and fighting plain-packaging laws—that mirror those used in the West decades ago. The 'smoke-free future' branding plays well in London boardrooms and Davos panels. In Jakarta and Nairobi, it's business as usual. As one WHO official remarked, 'They're selling cessation in Geneva and addiction in Lagos.'

What would a genuinely transformed tobacco industry look like? Independent researchers propose several litmus tests: voluntarily withdrawing cigarettes from markets where safer alternatives are available; supporting, rather than opposing, strong regulation of all nicotine products; opening proprietary research data to independent scrutiny; and accepting nicotine product standards that prioritize public health over profit maximization. No major tobacco company has met any of these standards. The closest analog may be the Swedish experience, where snus—a low-nitrosamine oral tobacco product—has been associated with the lowest smoking rates and lowest tobacco-related mortality in Europe. But snus succeeded despite, not because of, industry behavior; Sweden's cultural norms and regulatory framework drove the transition.

For consumers and policymakers, the appropriate posture is cautious engagement. Refusing to acknowledge that products like IQOS and Zyn are almost certainly less dangerous than combustible cigarettes denies adult smokers potentially life-saving alternatives. But granting tobacco companies the benefit of the doubt—accepting their transformation narrative at face value—ignores a century of documented bad faith. The path forward is *trust-but-verify* on a regulatory scale: authorize products based on independent scientific review, impose strict marketing limits that prevent youth targeting, require transparent post-market surveillance, and maintain the institutional memory of an industry that has earned every ounce of public skepticism directed its way. PMI says it wants to unsmoke the world. The world's response should be: prove it—under rules we write, not you.